Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | TACR1 | P25103 | 12/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28552636 | 0.83 | P2RX1 (0.42) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL27854715 | 0.83 | PRKCA (0.63) | IDO1PRKCAPRKCDMAOBEPHX1 | |
| SCHEMBL1282261 | 0.81 | GABRA1 (0.43) | IDO1TACR1 | |
| SCHEMBL3335304 | 0.81 | IDO1 (0.58) | IDO1MAOB | |
| SCHEMBL8838337 | 0.81 | IDO1 (0.53) | IDO1TACR1CES2PRKCAPRKCD | |
| SCHEMBL27255656 | 0.79 | IDO1 (0.50) | IDO1TACR1CES2PRKCAPRKCD | |
| SCHEMBL24142274 | 0.77 | IDO1 (0.49) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL805054 | 0.77 | IDO1 (0.49) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12831904 | 0.76 | IDO1 (0.47) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12758762 | 0.76 | IDO1 (0.47) | IDO1TACR1CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2004035587-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | TAC3, NTSR1, SCTR | IDO1 935/4885TACR1 8/4885CACNA1F 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.